AMAntonio Martínez-Yélamos

Antonio Martínez-Yélamos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antonio Martínez-Yélamos has a total of 243 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Aetiologic spectrum of longitudinally extensive spinal cord lesions and clues to their differential diagnosis

    by María Puche-Ribera, Pablo Arroyo-Pereiro, Isabel León, Laura Bau, Elisabet Matas, Lucía Romero-Pinel, Francisco Morandeira, Antonio Martínez-Yélamos, Sergio Martínez-Yélamos, Albert Muñoz-Vendrell

  • Open Access

    Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis

    by Albert Muñoz-Vendrell, Pablo Arroyo-Pereiro, Isabel León, Laura Bau, Elisabet Matas, Lucia Romero-Pinel, Sergio Roca-Pereira, Antonio Martínez-Yélamos, Sergio Martínez-Yélamos

    Background: Subcutaneous natalizumab offers greater convenience than intravenous administration, but pharmacokinetic differences have raised concerns about potential subclinical disease activity. Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) are sensitive biomarkers of neuroaxonal damage and astroglial activation. Methods: In this prospective, single-center cohort study, consecutive patients with relapsing–remitting multiple sclerosis who transitioned from intravenous to subcutaneous natalizumab were followed for 12 months. Serum sNfL and GFAP were measured at baseline (prior to switch), and at 6 and 12 months using SIMOA technology. Additional clinical outcomes included annualized relapse rate (ARR), EDSS, and MRI activity. Results: 23 patients were included (mean age 43.7 years; 91% female). Median disease duration was 14 years (IQR 8.1–22), median time on natalizumab was 5 years (IQR 3.3–7.9), baseline 2-year ARR was 0.09 ± 0.2, and median EDSS was 2.0 (IQR 2.0–3.5). Median sNfL Z -scores were 0.2 (IQR − 0.3–0.6) at baseline, 0.1 (IQR − 0.4–1.0) at 6 months, and 0.5 (IQR − 0.4–1.1) at 12 months, with no significant change over time ( p = 0.401). GFAP levels were similarly stable (87.7, 86.8, and 90.2 pg/mL; p = 0.957). ARR remained low and unchanged (0.09 pre- and post-switch; p = 1.0), with no radiological activity observed. EDSS remained stable over follow-up. Conclusions: In this small real-world cohort, switching from intravenous to subcutaneous natalizumab was associated with stable sNfL and GFAP levels over 12 months, alongside stable conventional clinical and MRI outcomes. These findings provide supplementary biomarker evidence broadly consistent with existing clinical trial and real-world data, but should be interpreted cautiously given the small sample size.

  • Open Access

    Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival

    by Sergio Roca‐Pereira, Yaiza López‐Sampere, Pol Mengod‐Soler, Mario Peña‐Fonteboa, Carla Marco, Alejandro Caravaca‐Puchades, Raúl Domínguez, Juan Francisco Vázquez‐Costa, Enrique Santamaría, Joaquín Fernández‐Irigoyen, et al.

    Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease primarily affecting motor neurons. Neurofilament light chain (NfL) is the most established prognostic biomarker; however, its diagnostic resolution is limited, particularly within intermediate concentration ranges, and it does not capture the molecular heterogeneity of ALS. This study aimed to identify complementary cerebrospinal fluid (CSF) biomarkers and pathway‐specific signatures through a non‐targeted multiomic approach. We performed SWATH‐MS‐based proteomics and LC–MS/MS lipidomics on CSF from ALS patients stratified by survival (ALS‐SS and ALS‐LS) and healthy controls. Weighted protein co‐expression network analysis (WPCNA) was applied to identify biologically coherent protein modules associated with disease phenotype and progression. Top biomarker candidates were further evaluated using immunoassays in an independent cohort. Post‐mortem ALS spinal cord tissues were analyzed to explore the pathophysiological relevance of identified proteins. CSF proteomic profiles robustly distinguished ALS patients from controls and stratified patient subgroups by survival, revealing a molecular signature characterized by inflammation, downregulation of detoxification mechanisms, and synaptic dysregulation in aggressive disease forms. In contrast, lipidomic profiles showed limited discriminatory power. WPCNA identified modular proteomic signatures capturing ALS heterogeneity, and machine learning models based on these profiles yielded optimal biomarker panels for diagnosis and prognosis. CXCL7 emerged as a promising complementary biomarker, and shed light in disease physiopathology. Immunoassay validation supported the diagnostic and prognostic potential of CXCL7 and its association with survival time. Histopathological analysis further confirmed CXCL7 localization in anterior horn motor neurons, despite no detectable changes in whole spinal cord lysates at late disease stages. Comprehensive CSF proteomic profiling, combined with network‐based analysis, enhances our understanding of ALS molecular heterogeneity and provides a framework for precision biomarker discovery. CXCL7 complements NfL as a diagnostic and prognostic biomarker, supporting improved patient stratification and advancing the development of personalized therapeutic strategies in ALS.

  • Open Access

    Benign multiple sclerosis and long-term outcomes after 30 years

    by E. Matas, L. Bau, L. Romero-Pinel, I. León, P. Arroyo-Pereiro, A. Muñoz-Vendrell, A. Martínez-Yélamos, S. Martínez-Yélamos

    Background: The concept of benign multiple sclerosis (MS) is a matter of debate. In most definitions, only the Expanded Disability Status Scale (EDSS) score and disease duration are considered, although other factors may influence a patient’s disability. The aims of this study were to evaluate the percentage of patients with benign MS in our cohort and to determine the proportion of these patients who remained benign after 20 and 30 years of disease evolution. Clinical and demographic variables related to this outcome were investigated. Methods: Patients fulfilling the criteria for benign MS (EDSS < 3.0 and at least 10 years of MS evolution) were selected from a hospital-based series and followed up prospectively. The EDSS was assessed after 20 and 30 years of MS evolution. Clinical and radiological variables were evaluated. Fatigue, depression and cognition tests were performed. Results: Eighty-two of the 485 patients evaluated in 1996 fulfilled the criteria for benign MS and were selected. In 51 of the 68 (75%) patients evaluated in 2006, the EDSS score continued to be ≤ 3. In 2016, 35 out of 58 (60%) patients continued to have an EDSS score ≤ 3. None of the clinical variables could predict persistence in the benign group. Eighteen of the 35 benign MS patients completed the questionnaires after 30 years. Fifty percent of them reported fatigue, 22% depression, and 83% had cognitive impairment. Conclusion: The majority of MS patients maintained a benign status even after 30 years of disease evolution. However, cognitive impairment in this group is notable.


  • Open Access

    3D T1 turbo spin echo improves detection of gadolinium-enhancing multiple-sclerosis lesions

    by Pablo Naval-Baudin, William F. Bermúdez Bravo, Vanessa I. Pineda-Borja, Pablo Arroyo-Pereiro, Ignacio Martínez-Zalacaín, Lucía Romero-Pinel, Paloma Mora, Nahum Calvo, Antonio Martínez-Yélamos, Sergio Martínez-Yélamos, et al.

    Objectives: To compare the performance of 3D T1 turbo spin echo (3DT1TSE) and 3D T1 turbo field echo (3DT1TFE) MRI in detecting gadolinium-enhancing lesions in multiple sclerosis (MS). Materials and methods: We retrospectively analyzed 255 3-T MRIs from MS patients, each including post-contrast 3DT1TSE and 3DT1TFE sequences. Two blinded readers independently assessed enhancing lesions per sequence. A consensus review, incorporating longitudinal imaging and additional sequences, served as the reference standard. Results: The consensus identified 70 enhancing lesions in 31 patients. All 70 were visible on 3DT1TSE, while 64 (91%) were detectable on 3DT1TFE. Reader sensitivity was higher for 3DT1TSE (84% and 90%) than 3DT1TFE (45% and 40%) (p < 0.01). Inter-reader agreement was excellent for 3DT1TSE (ICC = 0.90) and moderate for 3DT1TFE (intraclass correlation coefficient = 0.69). Although false positives were more common with 3DT1TSE, they were readily excluded during consensus reading. In six patients, enhancing lesions were detected only on 3DT1TSE, with treatment escalation in two. Conclusion: 3DT1TSE outperformed 3DT1TFE in sensitivity and reader agreement for enhancing lesion detection in MS. Incorporating 3DT1TSE into standard MRI protocols may improve disease activity assessment and clinical decision-making. Critical relevance statement: Replacing 3D gradient-echo with post-contrast 3D T1 turbo spin-echo brain MRI greatly improves the detection of gadolinium-enhancing multiple-sclerosis lesions, boosting diagnostic sensitivity and reader agreement and directly influencing treatment-escalation decisions in routine practice. Key Points: Detecting and enhancing MS lesions is limited by standard 3D T1 turbo field echo (3DT1TFE) MRI. 3D T1 turbo spin echo detects significantly more gadolinium-enhancing MS lesions than conventional 3DT1TFE. Greater lesion detection allows more precise activity assessment and optimal treatment management. Graphical


  • Open Access

    The 2024 McDonald criteria show comparable sensitivity to previous criteria for late-onset multiple sclerosis

    by Raquel Tena-Cucala, Pablo Naval-Baudin, Antonio Martínez-Yélamos, Isabel León, Albert Muñoz-Vendrell, Laura Bau, Elisabet Matas, Pablo Arroyo-Pereiro, Alejandro Caravaca Puchades, Francisco Morandeira, et al.


  • Open Access

    Assessment of the Multiple Sclerosis Severity Score and the Age-Related Multiple Sclerosis Severity Score as health indicators in a population-based cohort

    by Laura Bau, Elisabet Matas, Lucía Romero-Pinel, Isabel León, Albert Muñoz-Vendrell, Pablo Arroyo-Pereiro, Antonio Martínez-Yélamos, Sergio Martínez-Yélamos

    Background: People with multiple sclerosis (MS) present varying degrees of disability throughout their disease course. The Multiple Sclerosis Severity Score (MSSS) and the Age-Related Multiple Sclerosis Severity Score (ARMSSS) adjust the Expanded Disability Status Scale (EDSS) according to disease duration and age, respectively. These measures could be useful for quantifying MS severity and as health outcome indicators for benchmarking in population-based settings. The aim of this study was to describe the severity of MS in our health district using the MSSS and ARMSSS and to assess their consistency over time. Methods: This population-based study included patients from our health district who were diagnosed with MS according to the 2010 McDonald criteria, had a disease duration of at least one year and were followed up in our MS unit. Sex, age at onset, disease duration, clinical course, age and irreversible EDSS at the last follow-up visit were collected, and the MSSS and ARMSSS were calculated at two time points: 2017 and 2020. Results: One hundred seventy-seven patients were included in 2017, and 208 in 2020. The prevalence of MS was 90 and 104 per 100,000 inhabitants, respectively. The median MSSS was 1.77 (IQR 0.76–4.28) in 2017 and 2.03 (IQR 0.82–4.36) in 2020. The median ARMSSS was 2.90 (IQR 1.47–5.72) in 2017 and 2.93 (IQR 1.51–5.56) in 2020. No significant differences were found. Conclusions: According to the MSSS and ARMSSS, the severity of MS in our area is mild, and these instruments are consistent. These measures could be reliable health outcome measures.


  • Open Access

    The T1-dark-rim: A novel imaging sign for detecting smoldering inflammation in multiple sclerosis

    by Pablo Naval-Baudin, Albert Pons-Escoda, Albert Castillo-Pinar, Ignacio Martínez-Zalacaín, Pablo Arroyo-Pereiro, Susanie Flores-Casaperalta, Francis Garay-Buitron, Nahum Calvo, Antonio Martínez-Yélamos, Mònica Cos, et al.

    Objectives: Paramagnetic rim lesions (PRLs), usually identified in susceptibility-weighted imaging (SWI), are a promising prognostic biomarker of disability progression in multiple sclerosis (MS). However, SWI is not always available in clinical practice. The objective of this study is to define a novel imaging sign, the T1-dark rim, identifiable in a standard 3DT1 gradient-echo sequence, such as 3D T1 turbo field echo (3DT1FE) and explore its performance as a SWI surrogate to define PRLs. Materials & Methods: This observational cross-sectional study analyzed MS patients who underwent 3T magnetic resonance imaging (MRI) including 3DT1TFE and SWI. Rim lesions were evaluated in 3DT1TFE, processed SWI, and SWI phase and categorized as true positive, false positive, or false negative based on the value of the T1-dark rim in predicting SWI phase PRLs. Sensitivity and positive predictive values of the T1-dark rim for detecting PRLs were calculated. Results: Overall, 80 rim lesions were identified in 63 patients (60 in the SWI phase and 78 in 3DT1TFE; 58 true positives, 20 false positives, and two false negatives). The T1-dark rim demonstrated 97% sensitivity and 74% PPV for detecting PRLs. More PRLs were detected in the SWI phase than in processed SWI (60 and 57, respectively). Conclusion: The T1-dark rim sign is a promising and accessible novel imaging marker to detect PRLs whose high sensitivity may enable earlier detection of smoldering inflammation to guide MS treatment escalation. The relevance of T1-dark rim lesions that are negative on SWI opens up a new field for analysis.

  • Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim

    by Paula Lombardo-Del Toro, Irene Bragado-Trigo, Pablo Arroyo, Raquel Tena-Cucala, Laura Bau, Elisabet Matas, Albert Muñoz-Vendrell, Marta Simó, Albert Pons-Escoda, Antonio Martínez-Yélamos, et al.


  • Influence of Cardiovascular Risk Factors in Early Relapsing-Remitting Multiple Sclerosis: A Retrospective Analysis

    by Pablo Arroyo-Pereiro, Albert Muñoz-Vendrell, Laura Bau, Elisabet Matas, Lucia Romero-Pinel, Antonio Martínez-Yélamos, Sergio Martínez-Yélamos

    Introduction: Prior studies have suggested that cardiovascular risk factors (CVRFs) can affect the prognosis of multiple sclerosis (MS). The aim of this study was to assess if CVRFs affect the early course of MS. Methods: A retrospective observational study was performed, including patients diagnosed with relapsing-remitting MS (RRMS) from 2010 to 2020, with at least 2 years of disease and 6 months follow-up. Age at onset, disease duration, number of relapses, time to confirmed Expanded Disability Status Scale (EDSS) 3.0 and 6.0, and time to secondary progressive MS (SPMS) were collected. Presence and date at onset of hypertension (HT), diabetes mellitus (DM), high low-density lipoprotein cholesterol (LDLc), and smoking during the study period were collected. The primary objective was to assess if CVRFs at the onset of MS are associated with lower time to EDSS 3.0, time to EDSS 6.0, and time to SPMS, using bivariate and multivariate analysis. Results: 281 RRMS patients were included; median age at onset was 33 (IQR 26–39); 69.4% were female. Median EDSS at onset was 1.5 (IQR 1–2.5). Nine patients reached SPMS; 24 patients were diagnosed with HT, 9 with DM, 109 with high LDLc, and 123 were smokers during follow-up. No statistically significant association was found between the presence of CVRF at MS onset and the mentioned clinical outcomes during the MS course. Conclusion: No association was found between CVRFs and the early course of MS in our cohort.